Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Denmark / NCT03712722
Recruiting Observational

Fecal Microbiota Transplantation (FMT) for Clostridium Difficile

NCT03712722 · tracked via the Priya Life Science Denmark tracker
Sponsor
University of Aarhus
Phase
Observational
Started
2018-10-01
Last updated
2026-10-16

Condition(s) studied

Clostridium Difficile InfectionClostridioides Difficile Infection

Investigational drug(s) / intervention(s)

Faecal microbiota transplantation (FMT)

Faecal microbiota transplantation (FMT): FMT delivered by colonoscopy, nasojejunal tube, glycerol-based capsules, or freeze-dried encapsulated donor faeces

Study summary

Faecal microbiota transplantation (FMT) is used for Clostridioides difficile infection (CDI) as part of an quality improvement initiative and conducted within the framework of Center for Faecal Microbiota Transplantation at Aarhus University Hospital (CEFTA).

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * age 18 or higher * documented Clostridioides difficile infection Exclusion Criteria: * none

Primary outcome measure(s)

  • Resolution of Clostridium difficile-Associated disease (CDAD) — 8 weeks
    Number of patients with resolution of CDAD, , defined by the absense of diarrhea (3 or fewer bowel movements per day) and formed stools (Bristol 5 or lower) or, in the case of abnormal stool frequency or consistency, a negative Clostridium difficile toxin test week 8

Trial sites (1)

FacilityCityRegionStatus
Aarhus University Hospital Aarhus N Denmark Recruiting

More University of Aarhus trials in Denmark

The Role of Radiotherapy for the Management of Non-melanoma Skin Cancer in Denmark. Enrolling by invitation
Endometriosis, Food Consumption and Fertility Recruiting
Perioperative Treatment With Tranexamic Acid in Melanoma Recruiting
Nordic Randomized Trial on Laparoscopic Versus Vaginal Cerclage Recruiting
Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure Recruiting

Other trials for the same condition

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03712722 on ClinicalTrials.gov ↗ ← All trials in Denmark